Preferred Treatment in Pediatric Alopecia Areata
With a paucity of pediatric treatment evidence, researchers sought to evaluate current treatment for pediatric alopecia areata.
With a paucity of pediatric treatment evidence, researchers sought to evaluate current treatment for pediatric alopecia areata.
The first pill to treat adults with severe alopecia areata was approved by the U.S. Food and Drug Administration on Monday.
The THRIVE-AA1 trial included adults aged 18 to 65 years with moderate to severe alopecia areata who had at least 50% scalp hair loss.
The prevalence and incidence of pediatric alopecia areata across various factors is investigated.
Researchers sought to examine Alopecia Areata Symptom Impact Scale (AASIS) scores and clinician-assessed Severity of Alopecia Tool (SALT) scores and evaluate possible correlations.
Literature on clinical studies and reports investigating the association between new-onset alopecia areata or the exacerbation of preexisting alopecia areata following infection with SARS-CoV-2 are reviewed.
The efficacy of ritlecitinib in treating patients with alopecia areata is assessed.
The incidence of overall IBD, ulcerative colitis, and Crohn’s disease in patients with and without chronic inflammatory skin disease is compared.
Response differences among subgroups of patients with varying degrees of alopecia severity treated with baricitinib are assessed.
A study examines the epidemiology of alopecia areata in a population of exclusively Black patients.